Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Influenza, Human|Hepatitis B|Tetanus|Poliomyelitis|Diphtheria|Tetany|Hepatitis A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01090453 | P2 |
Completed |
Hepatitis B|Tetanus|Influenza, Human|Poliomyelitis|Diphtheria |
2011-10-11 |
2019-03-19 |
Treatments |
|
| NCT01171989 | P2 |
Completed |
Tetanus|Diphtheria|Influenza, Human|Tetany|Hepatitis B|Hepatitis A|Poliomyelitis |
2010-12-03 |
2020-01-28 |
Primary Endpoints|Start Date|Treatments |
|
| NCT00970307 | P2 |
Completed |
Tetanus|Poliomyelitis|Influenza, Human|Diphtheria|Hepatitis B |
2010-01-27 |
2020-01-04 |
Primary Endpoints|Start Date|Treatments |
|
| NCT00871741 | P2 |
Terminated |
Tetanus|Poliomyelitis|Diphtheria|Influenza, Human|Hepatitis B |
2009-06-25 |
2019-03-18 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|